Compare Davita Inc (DVA) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Philip Morris International Inc. — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Philip Morris International Inc. trades at $186.35 (market cap $289.90B). The key difference: Philip Morris International Inc. is far larger — about 24.7× Davita Inc's market cap, and Philip Morris International Inc. pays a 3.16% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PM | |
|---|---|---|
Market Cap | $11.72B | $289.90B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $200.17 |
52-Week Low | $103.87 | $144.33 |
Enterprise Value | $24.44B | $333.02B |
Dividend Yield | — | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Philip Morris International (PM) trades at $189.57, up 0.81% today, with a bullish technical outlook and strong fundamentals. Recent earnings beats in Q1 and Q2 2026, alongside a 27.91% net margin in 2025, highlight profitability. However, the company faces headwinds from a $500 million impairment charge and reduced 2026 guidance due to cost pressures, as reported by Reuters on June 2, 2026.
The stock offers a dividend yield supported by cash flow, but risks include regulatory challenges and currency volatility. Analysts maintain a buy consensus with a $211.17 target, suggesting 11% upside, though investors should weigh near-term earnings pressure against long-term brand strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
